• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

皮质醇合成抑制:一种针对抑郁症临床及内分泌表现的新治疗策略。

Cortisol synthesis inhibition: a new treatment strategy for the clinical and endocrine manifestations of depression.

作者信息

Thakore J H, Dinan T G

机构信息

Dept. of Psychological Medicine, St. Batholomew's Hospital, West Smithfield, London, UK.

出版信息

Biol Psychiatry. 1995 Mar 15;37(6):364-8. doi: 10.1016/0006-3223(94)00137-R.

DOI:10.1016/0006-3223(94)00137-R
PMID:7772644
Abstract

Evidence exists that oversecretion of cortisol may be responsible for the clinical manifestations and serotonergic abnormality in depressive illness. Using the cortisol synthesis inhibitor ketoconazole, we investigated the effects of directly lowering cortisol on the symptoms and the response of prolactin (PRL) to d-fenfluramine in eight patients suffering from major depression. Prolactin responses to d-fenfluramine were measured, and patients were treated with 400-600 mg of ketoconazole for 4 weeks, after which they were retested. Five patients treated with ketoconazole recovered from their depression, while the other three had decreases in their Hamilton Depression Rating Scale (HAMD) scores of < or = 50% and were deemed partial responders. Posttreatment prolactin responses to d-fenfluramine were higher than pretreatment values. Ketoconazole normalizes the blunted prolactin responses to d-fenfluramine and may be an effective method by which to treat depression. This implies that hypercortisolemia may be responsible for the clinical features and serotonergic subsensitivity observed in depression.

摘要

有证据表明,皮质醇分泌过多可能是导致抑郁症临床表现和血清素能异常的原因。我们使用皮质醇合成抑制剂酮康唑,对8例重度抑郁症患者进行研究,观察直接降低皮质醇水平对症状以及催乳素(PRL)对右芬氟拉明反应的影响。测量了催乳素对右芬氟拉明的反应,患者接受400 - 600毫克酮康唑治疗4周,之后再次进行检测。5例接受酮康唑治疗的患者抑郁症痊愈,另外3例汉密尔顿抑郁量表(HAMD)评分降低≤50%,被视为部分缓解者。治疗后催乳素对右芬氟拉明的反应高于治疗前值。酮康唑可使催乳素对右芬氟拉明的反应恢复正常,可能是一种有效的治疗抑郁症的方法。这意味着高皮质醇血症可能是抑郁症临床特征和血清素能亚敏感性的原因。

相似文献

1
Cortisol synthesis inhibition: a new treatment strategy for the clinical and endocrine manifestations of depression.皮质醇合成抑制:一种针对抑郁症临床及内分泌表现的新治疗策略。
Biol Psychiatry. 1995 Mar 15;37(6):364-8. doi: 10.1016/0006-3223(94)00137-R.
2
Depression in premenopausal women: gonadal hormones and serotonergic system assessed by D-fenfluramine challenge test.绝经前女性的抑郁症:通过D-芬氟拉明激发试验评估性腺激素和血清素能系统。
Prog Neuropsychopharmacol Biol Psychiatry. 2003 Jun;27(4):705-9. doi: 10.1016/S0278-5846(03)00085-X.
3
Multiple hormone responses to stimulation with dl-fenfluramine in patients with major depression before and after antidepressive treatment.重度抑郁症患者在抗抑郁治疗前后对dl-芬氟拉明刺激的多种激素反应。
Pharmacopsychiatry. 1990 Mar;23(2):76-84. doi: 10.1055/s-2007-1014487.
4
Fenfluramine challenge test as a predictor of outcome in major depression.芬氟拉明激发试验作为重度抑郁症预后的预测指标
Psychopharmacol Bull. 1993;29(2):155-61.
5
Antiglucocorticoid treatment of refractory depression with ketoconazole: a case report.酮康唑抗糖皮质激素治疗难治性抑郁症:一例报告
Biol Psychiatry. 1995 Mar 1;37(5):338-40. doi: 10.1016/0006-3223(94)00245-X.
6
Response to steroid suppression in major depression resistant to antidepressant therapy.
J Clin Psychopharmacol. 1991 Apr;11(2):121-6.
7
D-fenfluramine-induced prolactin and cortisol release in major depression: response to treatment.
J Affect Disord. 1992 Nov;26(3):143-50. doi: 10.1016/0165-0327(92)90009-u.
8
Outcome in delusional depression comparing trimipramine monotherapy with a combination of amitriptyline and haloperidol--a double-blind multicenter trial.比较三甲丙咪嗪单一疗法与阿米替林和氟哌啶醇联合疗法治疗妄想性抑郁症的疗效——一项双盲多中心试验。
J Psychiatr Res. 2009 Apr;43(7):702-10. doi: 10.1016/j.jpsychires.2008.10.004. Epub 2008 Nov 26.
9
Prolactin and cortisol responses to d-fenfluramine in major depression: evidence for diminished responsivity of central serotonergic function.
Am J Psychiatry. 1991 Aug;148(8):1009-15. doi: 10.1176/ajp.148.8.1009.
10
Possible use of glucocorticoid receptor antagonists in the treatment of major depression: preliminary results using RU 486.糖皮质激素受体拮抗剂在重度抑郁症治疗中的可能应用:使用RU 486的初步结果
J Psychiatry Neurosci. 1993 Nov;18(5):209-13.

引用本文的文献

1
Endocrinological Treatment Targets for Depressive Disorder.抑郁障碍的内分泌治疗靶点。
Adv Exp Med Biol. 2024;1456:3-25. doi: 10.1007/978-981-97-4402-2_1.
2
Efficacy of Treatments Targeting Hypothalamic-Pituitary-Adrenal Systems for Major Depressive Disorder: A Meta-Analysis.针对下丘脑-垂体-肾上腺系统治疗重度抑郁症的疗效:一项荟萃分析。
Front Pharmacol. 2021 Sep 10;12:732157. doi: 10.3389/fphar.2021.732157. eCollection 2021.
3
Antiglucocorticoids as Treatments for Depression : Rationale for Use and Therapeutic Potential.
抗糖皮质激素作为抑郁症的治疗方法:使用原理及治疗潜力
CNS Drugs. 1996 May;5(5):311-20. doi: 10.2165/00023210-199605050-00001.
4
Metyrapone in treatment-resistant depression.米替拉酮治疗抵抗性抑郁症。
Ther Adv Psychopharmacol. 2012 Aug;2(4):139-49. doi: 10.1177/2045125312436597.
5
Steroid psychosis: a review for neurosurgeons.类固醇性精神病:神经外科医生的综述。
J Neurooncol. 2012 Sep;109(3):439-47. doi: 10.1007/s11060-012-0919-z. Epub 2012 Jul 5.
6
Hormone treatment of depression.抑郁症的激素治疗
Dialogues Clin Neurosci. 2011;13(1):127-38. doi: 10.31887/DCNS.2011.13.1/rjoffe.
7
Glucocorticoid inhibition in the treatment of depression: can we think outside the endocrine hypothalamus?糖皮质激素抑制在抑郁症治疗中的应用:我们能否突破内分泌下丘脑的局限来思考?
Depress Anxiety. 2009;26(7):641-9. doi: 10.1002/da.20546.
8
Innovative approaches for the treatment of depression: targeting the HPA axis.抑郁症治疗的创新方法:针对下丘脑-垂体-肾上腺(HPA)轴
Neurochem Res. 2008 Apr;33(4):691-707. doi: 10.1007/s11064-007-9518-3. Epub 2007 Oct 25.
9
Psychotic major depression: a benefit-risk assessment of treatment options.精神病性重度抑郁症:治疗方案的获益-风险评估
Drug Saf. 2006;29(6):491-508. doi: 10.2165/00002018-200629060-00003.
10
[New developments in pharmacotherapy of depression].[抑郁症药物治疗的新进展]
Nervenarzt. 2004 Mar;75(3):273-80. doi: 10.1007/s00115-003-1517-2. Epub 2003 May 10.